Provided by Tiger Trade Technology Pte. Ltd.

GlaxoSmithKline PLC

50.29
+0.28000.56%
Pre-market: 50.19-0.1000-0.20%06:33 EDT
Volume:2.84M
Turnover:143.00M
Market Cap:101.72B
PE:16.08
High:50.71
Open:50.19
Low:50.06
Close:50.01
52wk High:61.70
52wk Low:39.29
Shares:2.02B
Float Shares:1.94B
Volume Ratio:1.13
T/O Rate:0.15%
Dividend:1.82
Dividend Rate:3.62%
EPS(TTM):3.13
EPS(LYR):3.74
ROE:33.38%
ROA:10.01%
PB:4.30
PE(LYR):13.46

Loading ...

GSK plc Stock (GSK) Moved Down by 3.06% on Jul 17: Drivers Behind the Movement

TradingKey
·
Jul 18

Movement Alert|GSK Falls 3.02% in Regular Trading, Discontinues Camlipixant Development After Phase 3 Failure in Refractory Chronic Cough

Market Focus
·
Jul 18

GSK’s ALANIS Trial: Fresh Momentum in AL Amyloidosis Could Reshape Investor Views

TIPRANKS
·
Jul 18

GSK Explores Heart Health Upside From Its Next-Gen Vaccines

TIPRANKS
·
Jul 18

GSK’s New Asthma Injection Study: Early Signals for Long-Term Investors

TIPRANKS
·
Jul 18

European Pharma Stocks' Underperformance Shouldn't Last

Dow Jones
·
Jul 17

GSK Oncology Portfolio Seems Underrated

Dow Jones
·
Jul 17

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investors Retreat From Chipmaker Stocks

MT Newswires Live
·
Jul 17

Sector Update: Healthcare

MT Newswires Live
·
Jul 17

GlaxoSmithKline (GSK) Gets a Buy from Jefferies

TIPRANKS
·
Jul 17

GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment

Dow Jones
·
Jul 17

GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan

TIPRANKS
·
Jul 17

GSK Will Likely Need to Book Write-down on Cough Drug Failure

Dow Jones
·
Jul 17

GSK Stops Camlipixant Program in Refractory Chronic Cough After Phase 3 Data

MT Newswires Live
·
Jul 17

Movement Alert|GSK Falls 4.42% in Pre-Market Trading, Trading at $50.41

Market Focus
·
Jul 17

GSK Halts Camlipixant Development in Chronic Cough After Mixed Phase III Results

TIPRANKS
·
Jul 17

GSK Advances New Infant Pneumococcal Vaccine Into Early-Stage Testing

TIPRANKS
·
Jul 17

GSK Rises Thursday, Outperforms Market

Dow Jones
·
Jul 17

GSK executives boost holdings via dividend-funded ADS purchases

TIPRANKS
·
Jul 16

GSK’s New Phase 3 Ovarian Cancer Trial Puts Mo-Rez in the First-Line Spotlight

TIPRANKS
·
Jul 16